Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Miller

Showing results (441-450 of 533) with videos related to

Pageof 54
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|March 20, 2012
Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trialD Craig Miller, Eugene H Blackstone, Michael J Mack, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 21, 2018
Observed to expected 30-day mortality as a benchmark for transcatheter aortic valve replacementMatthew C Henn, Alan Zajarias, Nishath Quader, et al.
Circulation. Cardiovascular Interventions|December 10, 2017
GDF-15 (Growth Differentiation Factor 15) Is Associated With Lack of Ventricular Recovery and Mortality After Transcatheter Aortic Valve ReplacementJuyong Brian Kim, Yukari Kobayashi, Kegan J Moneghetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancerMassimo Cristofanilli, Daniel F Hayes, G Thomas Budd, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 8, 2013
Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trialPamela S Douglas, Robert A Waugh, Gerald Bloomfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancerUgo De Giorgi, Vicente Valero, Eric Rohren, et al.
Journal of the American College of Cardiology|June 1, 2019
3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses: The PARTNER 2 RegistryJohn G Webb, Dale J Murdoch, Maria C Alu, et al.
Cancer Research|June 17, 2005
Global gene expression profiling of circulating tumor cellsDenis A Smirnov, Daniel R Zweitzig, Bradley W Foulk, et al.
Circulation. Cardiovascular Imaging|April 1, 2017
Computed Tomography Imaging Features in Acute Uncomplicated Stanford Type-B Aortic Dissection Predict Late Adverse EventsAnna M Sailer, Sander M J van Kuijk, Patricia J Nelemans, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 28, 2019
Inter- and intrasite variability of mortality and stroke for sites performing both surgical and transcatheter aortic valve replacement for aortic valve stenosis in intermediate-risk patientsKevin L Greason, Eugene H Blackstone, Jeevanantham Rajeswaran, et al.
Pageof 54

Showing results (441-450 of 533) with videos related to

Sort By:
Pageof 54
The Journal of Thoracic and Cardiovascular Surgery|March 20, 2012
Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trialD Craig Miller, Eugene H Blackstone, Michael J Mack, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 21, 2018
Observed to expected 30-day mortality as a benchmark for transcatheter aortic valve replacementMatthew C Henn, Alan Zajarias, Nishath Quader, et al.
Circulation. Cardiovascular Interventions|December 10, 2017
GDF-15 (Growth Differentiation Factor 15) Is Associated With Lack of Ventricular Recovery and Mortality After Transcatheter Aortic Valve ReplacementJuyong Brian Kim, Yukari Kobayashi, Kegan J Moneghetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancerMassimo Cristofanilli, Daniel F Hayes, G Thomas Budd, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 8, 2013
Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trialPamela S Douglas, Robert A Waugh, Gerald Bloomfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancerUgo De Giorgi, Vicente Valero, Eric Rohren, et al.
Journal of the American College of Cardiology|June 1, 2019
3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses: The PARTNER 2 RegistryJohn G Webb, Dale J Murdoch, Maria C Alu, et al.
Cancer Research|June 17, 2005
Global gene expression profiling of circulating tumor cellsDenis A Smirnov, Daniel R Zweitzig, Bradley W Foulk, et al.
Circulation. Cardiovascular Imaging|April 1, 2017
Computed Tomography Imaging Features in Acute Uncomplicated Stanford Type-B Aortic Dissection Predict Late Adverse EventsAnna M Sailer, Sander M J van Kuijk, Patricia J Nelemans, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 28, 2019
Inter- and intrasite variability of mortality and stroke for sites performing both surgical and transcatheter aortic valve replacement for aortic valve stenosis in intermediate-risk patientsKevin L Greason, Eugene H Blackstone, Jeevanantham Rajeswaran, et al.
Pageof 54